Astrazeneca Is Empowered By Optimism In Vaccine Trials
[ad_1] On the eve of the third quarter, investors again received good news from Astrazeneca. A final result from in-depth studies of its potential Covid-19 vaccine could be available by the end of this year, says the study’s chief investigator Andrew Pollard. His comments come days after the UK’s health authority, the regulator for medicines…